Equities

Gritstone bio Inc

Gritstone bio Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.5714
  • Today's Change-0.002 / -0.28%
  • Shares traded76.00
  • 1 Year change-71.43%
  • Beta0.5031
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. It has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.

  • Revenue in USD (TTM)15.65m
  • Net income in USD-144.89m
  • Incorporated2015
  • Employees231.00
  • Location
    Gritstone bio Inc5959 HORTON STREET, SUITE 300EMERYVILLE 94608United StatesUSA
  • Phone+1 (510) 871-6100
  • Fax+1 (510) 597-1488
  • Websitehttps://gritstonebio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bright Green Corp0.00-11.46m49.82m5.00--4.48-----0.0631-0.06310.000.05840.00----0.00-56.05---84.87-------------18,125.840.0289------52.54------
Odonate Inc0.00-102.07m50.02m137.00--1,844.41-----13.59-13.590.009.270.00----0.00-66.98-58.36-83.00-65.14------------0.00-------12.99------
Turnstone Biologics Corp0.00-74.92m52.04m82.00--0.6504-----3.53-3.530.003.460.00----0.00-80.25---94.45--------------0.00---73.66---78.05------
Rockwell Medical Inc86.62m-8.42m53.60m237.00--2.53--0.6188-0.3584-0.35843.330.69841.9013.2810.12365,485.20-18.47-46.29-27.53-65.3810.594.66-9.72-36.511.38-3.540.331--14.845.6954.82--76.21--
CEL-SCI Corp0.00-29.95m59.58m43.00--4.16-----0.6304-0.63040.000.26450.00-------87.78-70.19-103.56-78.31-------15,434.151.18-39.260.4319------13.99--223.59--
Gritstone bio Inc15.65m-144.89m62.04m231.00--4.01--3.97-1.57-1.570.170.14230.0901--40.5367,727.27-83.47-48.08-97.70-55.18-----926.13-573.71---554.880.7428---18.0568.96-15.71---4.19--
Immix Biopharma Inc0.00-18.21m64.72m14.00--2.32-----0.9263-0.92630.001.060.00----0.00-77.50---90.46--------------0.00-------87.44------
Marinus Pharmaceuticals Inc28.29m-145.34m66.47m165.00------2.35-2.64-2.640.5142-0.29920.15540.85363.72171,442.40-79.82-49.64-96.93-57.7691.22---513.80-518.962.93-13.621.29--21.63---613.59--7.47--
CASI Pharmaceuticals Inc28.94m-30.48m70.36m176.00--4.55--2.43-2.28-2.282.161.150.39541.003.41164,437.50-40.88-34.75-59.15-46.9158.3655.98-103.40-153.723.25-76.700.5458---21.41--34.27--14.65--
Eagle Pharmaceuticals Inc257.55m11.95m71.43m134.006.040.28582.190.27730.9110.91119.5919.250.65491.552.561,922,022.003.046.374.047.9869.8471.864.647.851.673.550.21780.0084.565.99513.14-8.42-49.05--
China Health Industries Holdings, Inc.95.95k-1.36m72.09m32.00------751.37-0.0208-0.02080.0015-0.03660.00370.503520.572,998.44-5.183.04-6.893.66-5.3469.55-1,419.4928.610.0377--1.76--41,225.93-55.72-15.49------
Journey Medical Corp80.00m-4.16m72.17m58.00--7.93--0.9021-0.3095-0.30954.130.64980.9852.274.281,379,276.00-5.12---17.85--66.22---5.20--0.93570.40490.5773--7.48--87.00------
SCYNEXIS Inc140.39m101.33m73.29m29.000.96420.989--0.52212.012.012.891.961.49--136.304,840,862.00107.48-30.02175.37-36.3588.97--72.18-86.76--193.810.1433--2,652.72252.64206.74------
Universe Pharmaceuticals Inc32.31m-6.16m74.25m225.00--0.2879--2.30-1.70-1.708.9110.910.57277.932.50143,594.40-10.925.31-14.347.0731.9346.26-19.086.252.43-28.050.12180.00-19.522.5329.46---21.17--
Assembly Biosciences Inc12.95m-51.36m74.32m65.00--2.04--5.74-11.22-11.222.765.950.1276--34.07199,200.00-50.60-39.69-66.58-44.03-----396.63-409.24----0.00-----13.5134.23---5.59--
Data as of Jul 03 2024. Currency figures normalised to Gritstone bio Inc's reporting currency: US Dollar USD

Institutional shareholders

32.06%Per cent of shares held by top holders
HolderShares% Held
Morgan Stanley & Co. LLCas of 31 Mar 20246.73m6.20%
Redmile Group LLCas of 31 Mar 20245.76m5.30%
BlackRock Fund Advisorsas of 31 Mar 20245.30m4.88%
The Vanguard Group, Inc.as of 31 Mar 20244.66m4.29%
Point72 Asset Management LPas of 31 Mar 20243.07m2.83%
DWS Investments (UK) Ltd.as of 31 Mar 20242.98m2.75%
Geode Capital Management LLCas of 31 Mar 20241.99m1.83%
SSgA Funds Management, Inc.as of 31 Mar 20241.80m1.66%
Ensign Peak Advisors, Inc.as of 31 Mar 20241.47m1.35%
Fidelity Management & Research Co. LLCas of 31 Mar 20241.04m0.96%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.